Aducanumab for the treatment of Alzheimer’s disease: a systematic review
![](https://sciaxis.org/wp-content/uploads/2023/06/colleagues-laboratory-doing-experiments.jpg)
![](https://sciaxis.org/wp-content/uploads/2023/06/colleagues-laboratory-doing-experiments.jpg)
Alzheimer’s disease is the most common cause of dementia, whose global frequency ranges from 60-70%. Despite the tremendous increase in AD prevalence and severity, only a few licensed medicines are available to treat the symptoms